GLENMARK Glenmark Pharmaceuticals Q4 FY25 results (Jan–Mar 2025) and concall
Glenmark Pharma reported a mixed Q4 FY25, with consolidated revenue growing 6.3% YoY to INR32,562 million and FY25 revenue up 12.8% to INR1,33,217 million. While Europe and ROW businesses showed strong performance, India formulation sales growth was muted at 0.4% due to market competition and strategic brand rationalization. North America revenue declined 5.4% in Q4, though an uptick is expected from FY26 with new launches. The company provided FY26 guidance of 10-12% revenue growth and 19-20% EBITDA margin.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 2,636 | 2,251 | 2,010 |
| EBITDA | 779 | 494 | 341 |
| Net profit | 595 | 414 | 148 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
